Jose Martinez-Raga

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3763286/jose-martinez-raga-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75 papers 25,566 29 h-index g-index

102 31,899 9.8 4.84 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
75	A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 965-976	3.1	
74	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. <i>JMIR Research Protocols</i> , 2021 , 10, e26214	2	
73	Developmental outcomes in adolescence of children with autism spectrum disorder without intellectual disability: A systematic review of prospective studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 126, 590-603	9	1
72	Empirical examination of executive functioning, ADHD associated behaviors, and functional impairments in adults with persistent ADHD, remittent ADHD, and without ADHD. <i>BMC Psychiatry</i> , 2020 , 20, 134	4.2	7
71	Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. <i>Drugs - Real World Outcomes</i> , 2020 , 7, 75-83	2.2	5
70	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020 , 49, 573-582	2.6	1
69	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , 2019 , 2019,	5	4
68	1st International Experts' Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation. <i>Frontiers in Psychiatry</i> , 2018 , 9, 54	5	20
67	The burden of disease in Spain: Results from the Global Burden of Disease 2016. <i>Medicina Clūica</i> , 2018 , 151, 171-190	1	55
66	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. <i>BMC Psychiatry</i> , 2018 , 18, 40	4.2	19
65	Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018 , 392, 1015-1035	40	1171
64	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018 , 63, 47-61	4	6
63	The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study. <i>International Journal of Public Health</i> , 2018 , 63, 25-37	4	31
62	Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018 , 392, 1684-1735	40	483
61	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018 , 391, 2236-2271	40	381
60	Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 629-633	2.2	16
59	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017 , 390, 231-266	40	352

58	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017 , 389, 1885-1906	40	867
57	Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2017 , 8, 87-99	3.5	19
56	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1084-1150	40	421
55	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1260-1344	40	1152
54	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1151-1210	40	2542
53	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1211-1259	40	3432
52	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1345-1422	40	1378
51	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017 , 390, 1423-1459	40	224
50	The Role of Education on Dual Disorders: A Discussion Paper. <i>Addictive Disorders and Their Treatment</i> , 2017 , 16, 155-163	0.5	
49	Joint statement on dual disorders: Addiction and other mental disorders. <i>Salud Mental</i> , 2017 , 40, 245-2	2 4 7.5	8
49 48	Joint statement on dual disorders: Addiction and other mental disorders. <i>Salud Mental</i> , 2017 , 40, 245-22. Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73	247.5 1	7
	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment,		
48	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73 Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015:	1	7
48	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73 Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016 , 3, e361-e387	7.8	7
48 47 46	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73 Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016 , 3, e361-e387 Nonmedical use of prescription drugs in the European Union. <i>BMC Psychiatry</i> , 2016 , 16, 274 State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and	7.8	7 382 88
48 47 46 45	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73 Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016 , 3, e361-e387 Nonmedical use of prescription drugs in the European Union. <i>BMC Psychiatry</i> , 2016 , 16, 274 State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain. <i>Journal of Dual Diagnosis</i> , 2016 , 12, 252-260 Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease	1 7.8 4.2	7 382 88 9
48 47 46 45 44	Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. <i>Revista De Psicologia De La Salud</i> , 2017 , 29, 71-73 Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016 , 3, e361-e387 Nonmedical use of prescription drugs in the European Union. <i>BMC Psychiatry</i> , 2016 , 16, 274 State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain. <i>Journal of Dual Diagnosis</i> , 2016 , 12, 252-260 Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1603-1658 Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.	1 7.8 4.2 2.4	7 382 88 9

40	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1725-1774	40	413
39	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016 , 388, 1813-1850	40	302
38	Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders. <i>Actas Espanolas De Psiquiatria</i> , 2016 , 44, 1-12	0.7	
37	Who says this is a modern disorder? The early history of attention deficit hyperactivity disorder. <i>World Journal of Psychiatry</i> , 2015 , 5, 379-86	3	10
36	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 1359-70	3.1	10
35	Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions. <i>International Journal of Adolescent Medicine and Health</i> , 2015 , 27, 163	-75 ¹	29
34	Dual diagnosis resource needs in Spain: a national survey of professionals. <i>Journal of Dual Diagnosis</i> , 2014 , 10, 84-90	2.4	11
33	Professionals' perceptions about healthcare resources for co-occuring disorders in Spain. <i>International Journal of Mental Health Systems</i> , 2014 , 8, 35	3.6	2
32	Validation of the Spanish version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). <i>Psicothema</i> , 2014 , 26, 180-5	2	11
31	Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. <i>CNS Drugs</i> , 2013 , 27, 15-30	6.7	87
30	Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. <i>International Journal of Adolescent Medicine and Health</i> , 2013 , 25, 231-43	1.1	19
29	Rethinking Dual Disorders/Pathology. Addictive Disorders and Their Treatment, 2013, 12, 1-10	0.5	23
28	Addressing Dual Diagnosis Patients Suffering from Attention-Deficit Hyperactivity Disorders and Comorbid Substance Use Disorders. <i>Addictive Disorders and Their Treatment</i> , 2013 , 12, 213-230	0.5	5
27	Nutritional Education of Secondary Education Students and Diet Quality 2013 , 207-218		
26	Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone () in Spain. <i>Health Economics Review</i> , 2012 , 2, 3	2	5
25	Consumo adictivo de sustancias psicoactivas. <i>Medicine</i> , 2011 , 10, 5800-5809	0.1	
24	A Review of E ncounter Groups for Addictions: The Therapeutic Community Training Series <i>Journal of Groups in Addiction and Recovery</i> , 2011 , 6, 338-338		
23	Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. <i>European Addiction Research</i> , 2010 , 16, 31-42	4.6	8

(2001-2008)

22	Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. <i>Current Drug Abuse Reviews</i> , 2008 , 1, 213-21		37
21	Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. <i>European Addiction Research</i> , 2007 , 13, 230-43	4.6	33
20	One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. <i>Drug and Alcohol Dependence</i> , 2007 , 86, 91-4	4.9	193
19	Does anyone care about names? How attendees at substance misuse services like to be addressed by health professionals. <i>European Addiction Research</i> , 2004 , 10, 75-9	4.6	8
18	Add-on gabapentin in the treatment of opiate withdrawal. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004 , 28, 599-601	5.5	34
17	The role of personality disorders on drug dependence treatment outcomes following inpatient detoxification. <i>European Psychiatry</i> , 2004 , 19, 187-92	6	19
16	Anorgasmia in a patient treated with bupropion SR for smoking cessation. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 460-1	1.7	4
15	Homosexual delusional jealousy in two heterosexual women. <i>Psychopathology</i> , 2003 , 36, 33-6	3.4	2
14	Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. <i>Addiction Biology</i> , 2003 , 8, 13-21	4.6	22
13	Emociones, motivacifi y trastornos adictivos: un enfoque biopsicosocial. <i>Trastornos Adictivos</i> , 2003 , 5, 335-345		
12	Unplanned versus planned discharges from in-patient alcohol detoxification: retrospective analysis of 470 first-episode admissions. <i>Alcohol and Alcoholism</i> , 2002 , 37, 277-81	3.5	58
11	Positive or negative history of childhood sexual abuse among problem drinkers: relationship to substance use disorders and psychiatric co-morbidity. <i>Journal of Substance Use</i> , 2002 , 7, 34-40	0.8	1
10	Interest in smoking cessation in a sample of Spanish alcohol and drug dependent patients. <i>European Neuropsychopharmacology</i> , 2002 , 12, 399	1.2	
9	Personalidades impulsivas y trastornos por uso de sustancias: algo ma que un diagnaticodual. <i>Trastornos Adictivos</i> , 2002 , 4, 216-222		2
8	Aspectos Eicos de la asistencia clEica en los trastornos adictivos. <i>Trastornos Adictivos</i> , 2002 , 4, 109-114		
7	Extrahepatic effects of alcohol: an overview 2002 , 467-485		1
6	Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit. <i>Addiction Biology</i> , 2001 , 6, 363-372	4.6	9
5	Los trastornos relacionados con el uso desustancias desde la perspectiva de lapsicopatolog y las neurociencias. <i>Trastornos Adictivos</i> , 2001 , 3, 164-171		6

4	Impact of family history of alcoholism on cocaine-induced subjective effects and pharmacokinetic profile. <i>Psychopharmacology</i> , 2000 , 152, 268-74	4.7	7
3	What Makes Alcohol-Dependent Individuals Early in Abstinence Crave for Alcohol: Exposure to the Drink, Images of Drinking, or Remembrance of Drinks Past?. <i>Alcoholism: Clinical and Experimental Research</i> , 1998 , 22, 1376-1381	3.7	17
2	Gender differences in cocaine dependent patients: a 6 month follow-up study. <i>Drug and Alcohol Dependence</i> , 1997 , 44, 35-40	4.9	102
1	The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study. <i>American Journal of Drug and Alcohol Abuse</i> , 1996 , 22, 173-84	3.7	12